Revised forecast
Fiscal year ending December 2026 · Second quarter (interim period)Previous forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In addition to strong business performance during the interim consolidated accounting period, the market entry of generic products for Zynrelef in the United States and Abilify Maintena in Europe was delayed beyond initial expectations. As a result of strong performance by key pharmaceuticals, the weaker yen, the discontinuation of development for certain indications of Urotrant, and shifts in the timing of expenses for development projects, revenue is expected to exceed the plan and research and development expenses are expected to fall below the plan.
| Item | Details |
|---|---|
| Net Sales | ¥1,218,000 million → ¥1,332,000 million（+9.4%） |
| Operating profit | ¥175,000 million → ¥278,000 million（+58.9%） |
| Profit attributable to owners of the parent | ¥128,000 million → ¥215,000 million（+68.0%） |
| Net income per share | ¥243.07 → ¥407.9 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue: ¥1,180,766 million; business profit: ¥239,221 million; operating profit: ¥242,118 million; interim profit before tax: ¥226,343 million; interim profit: ¥175,863 million; interim profit attributable to owners of the parent: ¥173,529 million; basic interim earnings per share: ¥326.12 |
| Reason for the revision | In addition to strong business performance during the interim consolidated accounting period, the market entry of generic products for Zynrelef in the United States and Abilify Maintena in Europe was delayed beyond initial expectations. As a result of strong performance by key pharmaceuticals, the weaker yen, the discontinuation of development for certain indications of Urotrant, and shifts in the timing of expenses for development projects, revenue is expected to exceed the plan and research and development expenses are expected to fall below the plan. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business performed strongly during the interim consolidated accounting period. Factors included delays in the market entry of generic products, strong performance by key pharmaceuticals, the weaker yen, and lower-than-expected research and development expenses due to discontinued development projects and shifts in the timing of expenses for development projects.